J
Jonathan W. Simons
Researcher at Prostate Cancer Foundation
Publications - 139
Citations - 24219
Jonathan W. Simons is an academic researcher from Prostate Cancer Foundation. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 54, co-authored 139 publications receiving 23331 citations. Previous affiliations of Jonathan W. Simons include Johns Hopkins University School of Medicine & Emory University.
Papers
More filters
Journal ArticleDOI
Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia.
Hua Zhong,Jonathan W. Simons +1 more
TL;DR: The results suggest that 28S rRNA is a reliable internal control for comparative analyses of transcription under hypoxia; GAPDH appears particularly unfavorable for this purpose either in Hypoxia or other experimental conditions that upregulate HIF-1alpha.
Journal ArticleDOI
Tracking the clonal origin of lethal prostate cancer.
Michael C. Haffner,Timothy Mosbruger,David M. Esopi,Helen Fedor,Christopher M. Heaphy,David Walker,Nkosi Adejola,Meltem Gürel,Jessica Hicks,Alan K. Meeker,Marc K. Halushka,Jonathan W. Simons,William B. Isaacs,Angelo M. De Marzo,William G. Nelson,Srinivasan Yegnasubramanian +15 more
TL;DR: This case illustrates the potential need in precision medicine to longitudinally sample metastatic lesions to capture the evolving constellation of alterations during progression and highlights the potential importance of developing and implementing molecular prognostic and predictive markers to augment current pathological evaluation and delineate clonal heterogeneity.
Journal Article
Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by ex Vivo Granulocyte-Macrophage Colony-stimulating Factor Gene Transfer
Jonathan W. Simons,Elizabeth M. Jaffee,Christine E. Weber,Hyam I. Levitsky,William G. Nelson,Michael A. Carducci,Audrey J. Lazenby,Lawrence K. Cohen,Christy C. Finn,Shirley M. Clift,Karen M. Hauda,Lisa A. Beck,Kristin M. Leiferman,Albert H. Owens,Steven Piantadosi,Glenn Dranoff,Richard C. Mulligan,Drew M. Pardoll,Fray F. Marshall +18 more
TL;DR: This Phase I study demonstrated the feasibility, safety, and bioactivity of an autologous GM-CSF gene-transduced tumor vaccine for RCC patients.
Journal Article
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
Theodore L. DeWeese,H. G. Van Der Poel,Shiyong Li,Bahar Mikhak,R. Drew,Marti Goemann,Ulrike M. Hamper,Robert DeJong,N. Detorie,Ronald Rodriguez,T. Haulk,Angelo M. DeMarzo,Steven Piantadosi,De-Chao Yu,Yun-Ching Chen,D. R. Henderson,Michael A. Carducci,William G. Nelson,Jonathan W. Simons +18 more
TL;DR: This study documents that intraprostatic delivery of CV706 can be safely administered to patients, even at high doses, and the data suggest that CV706 possesses enough clinical activity, as reflected by changes in serum PSA, to warrant additional clinical and laboratory investigation.
Journal ArticleDOI
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells
Tisheeka R. Graham,Haiyen E. Zhau,Valerie Odero-Marah,Adeboye O. Osunkoya,K. Sean Kimbro,Mourad Tighiouart,Tongrui Liu,Jonathan W. Simons,Ruth O'Regan +8 more
TL;DR: ZEB1 is identified as a key transcriptional regulator of EMT in prostate cancer and the role of insulin-like growth factor-I (IGF-I) in the regulation of ZEB1 during EMT associated with prostate tumor cell migration is investigated.